News | August 05, 2021
Lyka Labs reports improved set of numbers in Q1FY22
The company has been consistently reducing debt
The company has been consistently reducing debt
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
